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NeurodegenerationAmyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by the loss of
upper cortical and lower motor neurons. ALS causes death within 2–5 years of diagnosis. Diet and body mass
index inﬂuence the clinical course of disease, however there is limited information about the expression of
metabolic proteins and fat-derived cytokines (adipokines) in ALS. In healthy controls and subjects with ALS,
we have measured levels of proteins and adipokines that inﬂuence metabolism. We ﬁnd altered levels of active
ghrelin, gastric inhibitory peptide (GIP), pancreatic polypeptide (PP), lipocalin-2, plasminogen activator
inhibitor-1 (PAI-1), interleukin-6 (IL-6) and 8 (IL-8), and tumor necrosis factor alpha (TNFα) in the plasma of
ALS patients relative to controls. We also observe a positive correlation between the expression of plasma
nerve growth factor (NGF) relative to disease duration, and an inverse correlation between plasma glucagon
and the ALS functional rating scale-revised (ALSFRS-R). Further studies are required to determine whether
altered expression of metabolic proteins and adipokines contribute to motor neuron vulnerability and how
these factors act to modify the course of disease.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
that is characterized by the irreversible loss of upper cortical and
lower motor neurons. ALS causes death within 2–5 years of diagnosis,
generally due to respiratory failure [1]. The primary cause for ALS
remains unknown, but abnormal function and folding of proteins and
abnormal RNA processing [2–6], excitotoxicity [7], mitochondrial dys-
function [8], and astrocyte- [9] and microglial [10] toxicity are reported
to contribute to disease. Mutations in causative genes (e.g., SOD1 and
TDP-43) are associated with familial ALS, but have also been observed
in ALS cases with no known or obvious family history [11].
In the absence of curative therapies in ALS, it is important to identify
factors that modify the progression of disease. Metabolic abnormalitiesces, University of Queensland,
rst authors).
r B.V. This is an open access article uhave been described in ALS. These include hypermetabolism, which is
observed in both familial and sporadic ALS patients [12,13], decreasednu-
tritional intake [14], and weight loss resulting in a decline in body mass
index (BMI) [15]. The impact of altered metabolic balance on the course
of disease is demonstrated by the ﬁnding that correcting for
hypermetabolism improves survival in mouse models of ALS [16] and
that dietary supplementation of ALS patients provides some beneﬁt, pos-
sibly by maintaining body weight [17]. Indeed, ALS patients with a BMI
between 30 and 35 have better survival outcome [18], and a faster rate
of reduction in BMI throughout the course of ALS is highly correlated
with accelerated disease progression [15].
Whole body metabolism is regulated by a network of proteins and
peptides. Given the evidence of metabolic abnormalities in ALS, this
study aimed to determine whether ALS patients and age-matched
healthy subjects differ in levels of metabolic proteins and adipokines
that are involved in regulatingmetabolic homeostasis (targets assessed
in this study are listed in Supplementary Table 1). This study also aimed
to assess whether levels of these proteins and adipokines are associated
with BMI, disease duration, and functional capacity (determined by the
ALS functional rating scale-revised; ALSFRS-R) [19] of subjects with ALS.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical features of our patient cohort.
Control ALS p
Number of patients 34 68 NA
Age (mean, SD) (years) 57.3 (10.5) 60.4 (9.8) 0.14
Median, IQR 58.0, 50.0–66.3 63.0, 53.3–68.0
BMI (mean, SD) (kg/m2) 28.4 (4.2) 26.3 (5.1) 0.10
Median, IQR 27.9, 25.3–31.1 26.2, 22.5–30.4
Sex ratio (men/women) 23/11 47/21
ALSFRS-R score (mean,
minimum–maximum)
Male NA 36.6 (24–48)
Female NA 36.0 (25–44)
Familial/sporadic
Male NA 4/43
Female NA 3/18
Site of onset (upper/lower limb)
Male NA 23/24
Female NA 7/14
Riluzole
Male NA 18
Female NA 8
NA: non-applicable; and IQR: interquartile range.
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2.1. Study population
Ethical approval for the study was obtained from the Royal Brisbane
andWomen'sHospital (RBWH), TheWesleyHospital, and TheUniversity
of Queensland ethics committees. The study was conducted in accor-
dance with the principles set out in the Declaration of Helsinki. We
enrolled 68 ALS patients (30.9% female, 69.1% male) from the RBWH
Motor Neuron Disease Clinic between March 2010 and March 2014. For
healthy controls, we enrolled 34 age-matched healthy volunteers from
the RBWH, The Wesley Hospital, and The University of Queensland.
Control subjects were not suffering from any disease condition and
were not genetically related to the ALS patients recruited into this
study. ALS patients had clinically deﬁnite or probable ALS (10.3% familial.
89.7% sporadic) according to the revised El Escorial criteria [20]. The clin-
ical details of the patients are listed in Table 1. To be included in the study,
patientswere required to have onset of disease in the limbs. Patientswith
bulbar onset were excluded due to swallowing problems associatedwithTable 2
Comparison of the expression of metabolic markers and adipokines between control subjects a
Control 95% CI (range)
Metabolic factors
Amylin (pg/ml) 26.3 (14.4) 21.3–31.4
c-Peptide (ng/ml) 3.4 (1.9) 2.69–4.05
Ghrelin (pg/ml) 25.1 (28.2) 15.3–35.0
GIP (ng/ml) 0.4 (0.3) 0.303–0.484
GLP-1 (pg/ml) 30.3 (35.7) 345–627
Glucagon (pg/ml) 44.1 (34.1) 31.6–56.6
Insulin (pg/ml) 53.4 (46.4) 37.2–69.6
PP (pg/ml) 485.7 (404.0) 345–627
PYY (pg/ml) 172.8 (123.2) 130–216
Adipokines
Adiponectin (mg/ml) 26.7 (22.7) 18.7–34.8
HGF (pg/ml) 352.9 (211.3) 279–426
IL-6 (pg/ml) 3.0 (2.4) 2.07–3.81
IL-8 (pg/ml) 3.1 (2.5) 2.23–3.97
Leptin (ng/ml) 17.2 (27.2) 7.51–26.8
Lipocalin-2 (ng/ml) 104.3 (40.8) 90.1–119
MCP-1 (pg/ml) 161.6 (76.1) 135–188
NGF (pg/ml) 8.0 (4.1) 6.59–9.45
PAI-1 (ng/ml) 55.5 (39.8) 41.6–69.3
Resistin (ng/ml) 57.6 (37.0) 44.7–70.5
TNFα (pg/ml) 3.1 (1.4) 2.59–3.56
⁎ denotes signiﬁcance at p ≤ 0.05; ⁎⁎ denotes signiﬁcance at p ≤ 0.01.bulbar symptoms. There was no signiﬁcant difference between controls
and ALS subjects in age or BMI. The functional status of ALS patients
was evaluated using the ALSFRS-R [19]. All patients provided consent to
participate in the study.
2.2. Plasma collection
Blood samples were collected between 1000 h and 1430 h into 4 ml
BD Vacutainers® containing 1267.2 mg of the anti-coagulant K2EDTA
(BD, Franklin Lakes, NJ, USA). Samples were centrifuged for 3 min
at 3600 rpm. Plasma was collected, frozen on dry ice, and stored at
−80 °C for further analysis. The duration of disease from onset of
symptoms to the date of collection was recorded.
2.3. Multiplex assays
Plasma samples were treated with a protease inhibitor cocktail
(Millipore,MA,USA;mM:200AEBSF, 0.16 bovine aprotinin, 10 bestatin,
3 E-64 protease inhibitor, 4 leupeptin, 2 pepstatin A), dipeptidyl pepti-
dase 4 (DPP-IV; Millipore; 50 mM), and aprotinin (Sigma, MO, USA;
200 mg/ml) and phenylmethanesulfonylﬂuoride (PMSF; Sigma; 0.1
mg/ml). Magnetic multiplex assays were performed according to the
manufacturer's instructions (Millipore). Targets on the humanmetabol-
ic hormone assay (HMHMAG-34K) were: total amylin, c-peptide, GIP,
ghrelin (active), glucagon, glucagon-like peptide-1 (GLP-1, active), PP
and peptide YY (PYY). Targets on the human adipokine assays
(HADK1MAG-61K and HADK2MAG-61K) were: adiponectin, hepatocyte
growth factor (HGF), insulin, IL-6, IL-8, leptin, lipocalin-2, monocyte
chemoattractant protein-1 (MCP-1), NGF, total PAI-1, resistin, and
TNFα. The origin and biological function of these targets are summarized
in Supplementary Table 1.
2.4. Statistical analysis
Data were analyzed using Prism 6.0c (Graphpad Software Inc., CA,
USA). Normality of residuals (distribution)within control or ALS groups
for all measures was assessed by Shapiro–Wilk W test. Differences
between groups were determined by Mann–Whitney U test. The
strength of associations between metabolic proteins and adipokines
and BMI, ALSFRS-R scores and disease duration was determined by
Spearman's rank correlation coefﬁcient analysis. Data in tables arend amyotrophic lateral sclerosis (ALS) patients.
ALS 95% CI (range) p
31.8 (36.3) 23.0–40.6 0.40
3.7 (5.5) 2.39–5.05 0.72
13.2 (11.2) 10.5–15.9 b0.01⁎⁎
0.3 (0.3) 0.21–0.33 b0.01⁎⁎
28.5 (30.7) 230–379 0.80
37.7 (24.1) 31.8–43.7 0.30
46.6 (51.7) 34.1–59.1 0.52
304.5 (305.5) 231–378 b0.01⁎⁎
158.9 (107.3) 133–185 0.56
40.1 (45.4) 29.1–51.2 b0.05⁎
401.0 (260.2) 338–464 0.35
9.0 (22.4) 3.59–145 b0.05⁎
4.6 (2.6) 3.93–5.21 b0.01⁎⁎
15.0 (27.5) 8.25–21.7 0.71
123.9 (40.9) 114–134 b0.05⁎
164.6 (76.8) 146–183 0.83
10.3 (21.9) 4.98–15.6 0.55
95.9 (60.6) 81.2–111 b0.01⁎⁎
66.2 (39.3) 56.7–75.7 0.30
3.7 (1.4) 3.40–4.07 b0.01⁎⁎
Fig. 1.Correlation analysis of plasmametabolic proteins and adipokines inhealthy controls
andpatientswith amyotrophic lateral sclerosis (ALS). (A) BMI correlatedwith levels of leptin,
(B) plasminogen activator inhibitor 1 (PAI-1), and (C) monocyte chemoattractant protein-1
(MCP-1) in the controls. For the ALS cohort, plasma levels of (A) leptin, (D) insulin, and (E) c-
peptide increased relative to an increase in BMI. (F) Plasma adiponectin was inversely corre-
lated with BMI in the ALS cohort. (G)Measures of BMI in ALS patients did not correlate with
ALSFRS-R. (H) The inverse relationship between BMI and disease duration did not reach sig-
niﬁcance. (I) A signiﬁcant inverse correlation exists between circulating levels of glucagon
and ALSFRS-R, and (J) a positive correlation exists between circulating levels of NGF and dis-
ease duration.
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signiﬁcance.
3. Results
3.1. Expression of metabolic proteins and adipokines in ALS patients
and controls
The expression of human metabolic proteins and adipokines in ALS
patients and controls is presented in Table 2. For metabolic proteins,
there was no difference in levels of total amylin, c-peptide, active GLP-
1, glucagon, insulin, and PYY between controls and ALS patients. The
plasma concentration of active ghrelin, GIP and PP was signiﬁcantly
lower in ALS patients than controls. For adipokines, there was no differ-
ence in levels of HGF, leptin, MCP-1, NGF, and resistin between controls
and ALS patients. Circulating levels of adiponectin, IL-6, IL-8, lipocalin-2,
PAI-1, and TNFα were signiﬁcantly higher in ALS patients than in con-
trols. Riluzole had no effect on the expression of any of the metabolic
proteins and adipokines.
Of the factors that showed signiﬁcant differences between ALS
subjects and controls, ghrelin, adiponectin, IL-6, IL-8 and TNFα were
differentially affected by gender within the ALS cohort (Supplementary
Table 2). Ghrelin, whichwas reduced in the ALS group,was signiﬁcantly
lower in female ALS subjects. Adiponectin, which was higher in ALS
subjects, was higher in female ALS subjects. IL6, IL8 and TNFα, which
were higher in ALS subjects, were lower in female ALS subjects.
3.2. Correlation analysis of plasma metabolic proteins and adipokines with
clinical features
3.2.1. Correlation of plasma metabolic proteins and adipokines with BMI
Of the 34 healthy subjects and 68 ALS patients, measures of BMI were
available from 25 and 46 persons respectively. Supplementary Table 3
summarizes Spearman correlation analyses and comparisonofﬁt formet-
abolic proteins and adipokines relative to BMI in controls and ALS pa-
tients. BMI was signiﬁcantly correlated with levels of leptin, PAI-1, and
MCP-1 in the controls (Fig. 1A–C). For the ALS cohort, we observed signif-
icant positive correlation of plasma leptin, insulin and c-peptide with
BMI (Fig. 1A, D and E). Plasma adiponectin showed a signiﬁcant inverse
correlation with BMI in ALS (Fig. 1F). We found no correlation between
BMI and ALSFRS-R (Fig. 1G) or BMI and disease duration (Fig. 1H).
3.2.2. Correlation of plasma metabolic proteins and adipokines with
ALSFRS-R and disease duration
The correlation between levels ofmetabolic proteins and adipokines
with ALSFRS-R scores and disease duration are shown in Supplementary
Table 4. There was a signiﬁcant inverse correlation between the expres-
sion of circulating levels of glucagon and ALSFRS-R in ALS patients
(Fig. 1I). Therewas a signiﬁcant positive correlation between circulating
levels of NGF and disease duration in ALS patients (Fig. 1J).
4. Discussion
We present data showing differing levels of metabolic proteins and
adipokines between ALS patients and healthy controls. The potential
metabolic consequences of our ﬁndings speciﬁc to ALS are discussed
below and are listed in Table 3.
We found lower circulating levels of ghrelin, GIP and PP in ALS
patients. Ghrelin is an appetite stimulating hormone [21], so low levels
of ghrelinmay contribute to reduced total food intake, and consequently
malnutrition and reduced survival in ALS [22]. Indeed, ghrelin adminis-
tration promotes food intake and prolongs survival in a mouse model
of ALS [23]. Consistent with reduced food intake in ALS, we observe
lower levels of GIP and PP in ALS patients. GIP stimulates insulin secre-
tion in response to food intake [24], whereas PP mediates peripheral
insulin action [25]. Reduced levels of GIP and PP in our ALS cohort mayprovide a mechanism for the diminished peripheral insulin action and
glucose intolerance observed in ALS [26].
We observed increased expression of a number of adipokines that are
linked tometabolic disease. Adiponectin regulates glucose and fatty acid
oxidation [27], chronic elevation of IL-6 promotes hepatic insulin resis-
tance [28] while acute elevation of IL-6 promotes the supply of glucose
and fat to skeletal muscle [29]. IL-8 is correlated with insulin resistance
in obesity and metabolic syndrome [30,31] while PAI-1 is associated
25S.T. Ngo et al. / Journal of the Neurological Sciences 357 (2015) 22–27increased visceral fat mass [32] and insulin resistance in lean individuals
[33]. Lipocalin-2 is associated with increased total energy expenditure
and increased fat oxidation [34], and TNFα induces lipolysis [27]. There-
fore, the increased expression of adiponectin, IL-6, IL-8, lipocalin-2, PAI-
1 and TNFα thatwe observe in ALSmay contribute to the reported occur-
rence of glucose intolerance and insulin resistance [26,35], hypermetabo-
lism [12,13] and the loss of fat mass [18] that is seen in ALS. Nonetheless,
the mechanism for the increase in the expression of these adipokines
might also be inherent to pathologies associated with ALS. Indeed, it is
possible that IL-6, IL-8, and TNFα originate from the activation of innate
immunity [36] and primed astrocytes [37], while lipocalin-2 may
originate from activated microglia [38].
Consistent with observations that leptin is secreted proportionate to
fat mass [39], BMI was positively correlated with circulating measures
of leptin in the control and ALS cohorts. Since levels of PAI-1 [40] and
MCP-1 [31] are positively associated with BMI, the correlation between
levels of PAI-1 and MCP-1 with BMI in our control cohort is to be
expected. In contrast, we observed no association between PAI-1
and MCP-1 with BMI in our ALS cohort. PAI-1 and MCP-1 are asso-
ciated with changes in the distribution of or mass of visceral fat [32,
41]. Therefore, the increased visceral fat mass and the increased
ratio of visceral to subcutaneous fat that is seen in ALS [42] might
underlie the greater variability in circulating levels of PAI-1 and
MCP-1 and consequently the lack of association between PAI-1
and MCP-1 and BMI in the ALS cohort.
Insulin and c-peptide are associated with increased adiposity and
BMI. Thus, the relationship between insulin and BMI in subgroup of
control and ALS subjects that were BMI-matched, and the lack of devia-
tion in this relationship between the two cohorts is to be expected. As c-
peptide is co-secretedwith insulin, our observations that BMI correlated
with c-peptide levels in the ALS cohort mirror the positive correlation
between insulin and BMI.Table 3
Summary of the observed changes in metabolic proteins and adipokines in amyotrophic latera
Hormone/peptide Regulation
in ALS
Relation to
BMI in ALS
Relation to
ALSFRS-R
Relation to di
duration
Metabolic Factors
C-peptide No change Positive correlation No correlation No correlatio
Ghrelin Decreased No correlation No correlation No correlatio
GIP Decreased No correlation No correlation No correlatio
Glucagon No change No correlation Negative
correlation
No correlatio
Insulin No change Positive correlation No correlation No correlatio
PP Decreased No correlation No correlation No correlatio
Adipokines
Adiponectin No change Negative
correlation
No correlation No correlatio
IL-6 Increased No correlation No correlation No correlatio
IL-8 Increased No correlation No correlation No correlatio
Leptin No change Positive correlation No correlation No correlatio
Lipocalin-2 Increased No correlation No correlation No correlatio
NGF No change No correlation No correlation Positive
correlation
PAI-1 Increased No correlation No correlation No correlatio
TNFα Increased No correlation No correlation No correlatioWhile adiponectin is inversely associatedwith fatmass [43], the lack
of relationship between circulating levels of adiponectin and BMI are in
line with observations that BMI does not independently affect plasma
adiponectin levels in healthy lean and obese individuals [44]. The
majority of our control and ALS patients fell within the healthy to over-
weight BMI range, yet we observed a negative association between
adiponectin and BMI in ALS patients. Since adiponectin levels are corre-
lated with the development of metabolic complications of adiposity
[45], our data support previous observations of increased central obesity
[42] and insulin resistance [35] in ALS.
We found that lower levels of circulating glucagon were associated
with higher ALSFRS-R scores. This suggests that an increase in disease
severity in ALSpatients is correlatedwith increased circulating glucagon
levels. Indeed, given that impaired glucose homeostasis in ALS could
occur as a consequence of higher levels of circulating glucagon [46],
our data is congruentwith observations that insulin resistance is related
to disease severity and outcome in ALS [47].
In our ALS patients, NGF levels correlatedwith disease duration. This
may be related to increased fat mass, as is seen in obesity andmetabolic
syndrome [48]. As we observed no relationship between BMI and
disease duration in our ALS cohort, it seems unlikely that the association
of NGF with disease duration is linked with metabolic derangements
associated with fat mass. Rather, increased NGF in patients with longer
disease duration may underlie reduced food intake, since NGF sup-
presses food intake [49]. Alternatively, the increase in circulating NGF
in our ALS cohortmay arise from increased expression of NGF in skeletal
muscle [50] or altered astrocyte–motoneuron cross-talk [51]. This was
not directly assessed in this study.
While the ALS subjects in this study were typical of a clinical popu-
lation in that approximately 10% had familial ALS, we excluded patients
with bulbar onset disease to remove any metabolic disturbance that
might occur from malnutrition due to an inability to eat. Although thel sclerosis (ALS).
sease Possible metabolic consequences in ALS
n Impaired C-peptide release may underlie impaired insulin function and
glucose homeostasis in ALS. Unlikely as secretion appears to be normal.
n Reduced hunger leading to reduced food intake and possibly weight loss.
n Reduced insulin secretion resulting in reduced capacity to use glucose as
energy; reduced lipogenesis resulting in an inability to accumulate fat mass.
n Impaired capacity to increase circulating levels of glucose; impaired glucose
tolerance resulting in reduced capacity to use glucose as energy. May not be
reﬂected by circulating levels.
n Impaired insulin action thought to contribute to impaired glucose tolerance
resulting in impaired capacity to use glucose as energy. May not be reﬂected by
circulating levels.
n Reduced peripheral insulin action resulting in reduced capacity to use glucose as
energy; decreased secretion of gastric juices resulting in gastrointestinal
dysfunction.
n Increased risk of metabolic derangements associated with increased fat mass
(eg. insulin resistance).
n May contribute to the development of insulin resistance resulting in reduced
capacity to use glucose as energy.
n May contribute to the development of insulin resistance resulting in reduced
capacity to use glucose as energy.
n Increased satiety relative to fat mass resulting in reduced food intake as a
means to modulate energy balance.
n Increased total energy metabolism and increased breakdown of fat leading to
depletion of fat mass and subsequent weight loss and reduced BMI.
Increase relative to disease duration may reﬂect reduced food intake.
n May contribute to the development of insulin resistance resulting in reduced
capacity to use glucose as energy.
n Induction of lipolysis resulting in the breakdown and mobilization of fat
stores and subsequent weight loss and reduced BMI.
26 S.T. Ngo et al. / Journal of the Neurological Sciences 357 (2015) 22–27patients were studied at the same time of day, we did not control for
food intake. Meal patterning inﬂuences the majority of metabolic pro-
teins. Although we observed clear and consistent differences between
ALS patients and healthy controls, our data need to be conﬁrmed in a
study that strictly controls for food intake, and that is extended to
patients with bulbar onset disease.
Under normal physiological conditions, the expression of metabolic
proteins and adipokines varies relative to BMI and age. Given that BMI
valueswere onlymatched for a subset of our control andALS populations,
we cannot exclude that the altered expression of metabolic proteins and
adipokines observed in this study might be related to BMI. However, in
contrast to previous reports [16,21,47], we found no correlation between
BMI and disease severity or disease duration in our ALS patients with
known BMI. Given that our measures do not account for the progressive
weight loss that is seen in ALS patients during disease progression, long-
term serial assessment of the relationship between BMI and ALSFRS-R
or disease duration is also needed to assess associations between BMI
and disease severity, and BMI and disease progression.
Gender impacts the prevalence and severity of ALS [52], and thus
gender-effects may contribute to the differential expression ofmetabol-
ic proteins and adipokines between ALS patients and controls. Levels of
amylin, ghrelin, adiponectin, HGF, IL-6, IL-8, resistin and TNFα differed
between male and female ALS patients. Of these, amylin, ghrelin, HGF,
and IL-8 levels varied from anticipated gender speciﬁc differences that
would normally be observed [53–56]. How differential expression of
these factors may impact disease prevalence, severity and possibly
progression remains completely unexplored.
Finally, while metabolic abnormalities have been described in famil-
ial and sporadic cases of ALS [12,13], it is possible that the heterogeneity
of ALS may lead to varying degrees of metabolic dysfunction between
patients with different ALS genotypes and phenotypes. Thus, there is a
need for studying metabolic disturbances across the whole spectrum
of ALS.
In summary, we observe a number of alterations in the expression
of metabolic proteins and adipokines between ALS patients and BMI
matched controls. These data, in combination with current clinical
observations of the impact of altered metabolic balance in ALS, provide
evidence to substantiate the existence of metabolic responses in ALS,
and shed light on altered homeostatic processes in this complex disease.
Future studies are needed to determine whether altered expression of
metabolic proteins and adipokines contribute tomotor neuron vulnera-
bility, or whether/how these factors act to modify the course of disease.
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